FY2024 Earnings Estimate for BioAtla Issued By HC Wainwright

BioAtla, Inc. (NASDAQ:BCAB - Free Report) - HC Wainwright issued their FY2024 earnings per share estimates for BioAtla in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. He expects that the company will earn ($1.46) per share for the year. HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for BioAtla's current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for BioAtla's Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.99) EPS.

BioAtla (NASDAQ:BCAB - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same quarter last year, the company posted ($0.70) earnings per share.

Separately, JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of BioAtla in a research report on Monday, September 16th.

BioAtla Stock Down 8.8 %

BCAB traded down $0.15 during trading on Friday, reaching $1.56. 1,726,550 shares of the stock traded hands, compared to its average volume of 854,883. The stock's 50-day moving average is $1.92 and its 200 day moving average is $1.88. BioAtla has a 12 month low of $1.14 and a 12 month high of $4.02. The stock has a market capitalization of $75.40 million, a PE ratio of -0.91 and a beta of 1.03.

Hedge Funds Weigh In On BioAtla

Several hedge funds have recently modified their holdings of BCAB. Vontobel Holding Ltd. purchased a new stake in shares of BioAtla during the third quarter worth $28,000. Ground Swell Capital LLC bought a new position in BioAtla in the 2nd quarter worth about $33,000. Valmark Advisers Inc. purchased a new position in BioAtla during the 2nd quarter valued at about $34,000. Rinkey Investments bought a new stake in shares of BioAtla during the second quarter valued at about $35,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in shares of BioAtla in the third quarter worth about $44,000. Institutional investors own 77.23% of the company's stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.